Zacks Investment Research
03 Nov 2026, 23:51 UTC · 20m ago
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
Impact · against what's priced in
Corcept's Q3 earnings beat provides data that supports the bullish growth trajectory but does not fundamentally shift the stock's valuation, as the current price already incorporates the company's raised FY2025 guidance and recent product approvals. The results confirm the company is meeting the demanding growth path the market expects, but they do not yet prove the long-term peak revenue targets that the market is not yet paying for.
- CORT+0.10
Already priced in
- The price assumes
The raised FY2025 revenue guidance of $950 million to $1.05 billion is fully reflected
The reported Q3 revenue of $340.47 million and EPS of $1.01 confirm that the company is tracking toward the raised FY2025 guidance and the 25.1% revenue CAGR the price already assumes.
What CORT's price assumes · Sep 14
Search tags
